APA (7th ed.) Citation

L, H., MV, N., SS, D., R, C., A, R., JM, B., . . . J, Z. (2020). Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 15(9), 1449. https://doi.org/10.1016/j.jtho.2020.04.026

Chicago Style (17th ed.) Citation

L, Hong, et al. "Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 15, no. 9 (2020): 1449. https://doi.org/10.1016/j.jtho.2020.04.026.

MLA (9th ed.) Citation

L, Hong, et al. "Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 15, no. 9, 2020, p. 1449, https://doi.org/10.1016/j.jtho.2020.04.026.